Cost-effectiveness of Pegfilgrastim versus Filgrastim after high-dose chemotherapy and autologous stem cell transplantation in patients with lymphoma and myeloma - HAL-SHS - Sciences de l'Homme et de la Société Accéder directement au contenu
Article Dans Une Revue Applied Health Economics and Health Policy Année : 2013

Cost-effectiveness of Pegfilgrastim versus Filgrastim after high-dose chemotherapy and autologous stem cell transplantation in patients with lymphoma and myeloma

Fichier non déposé

Dates et versions

halshs-00752571 , version 1 (16-11-2012)

Identifiants

Citer

Lionel Perrier, Anne Lefranc, Philippe Quittet, Philippe Moreau, Carole Siani, et al.. Cost-effectiveness of Pegfilgrastim versus Filgrastim after high-dose chemotherapy and autologous stem cell transplantation in patients with lymphoma and myeloma. Applied Health Economics and Health Policy, 2013, 11 (2), pp. 129-138. ⟨10.1007/s40258-013-0011-7⟩. ⟨halshs-00752571⟩
236 Consultations
0 Téléchargements

Altmetric

Partager

Gmail Facebook X LinkedIn More